Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,235 from $1,183 and keeps a Buy rating on the shares. The firm updated its model following Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026
- Eli Lilly Shareholders Back Board, Maintain Governance Structure
- Morning News Wrap-Up, 5/7/26: Today’s Biggest Stock Market Stories!
- Lilly and Regeneron Advance Obesity Combo Bet as Key Tirzepatide Trial Reaches Completion
- Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential